Vifor Pharma

Vifor Pharma EBITDA

Delisted·Dec 22, 2022

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Vifor Pharma (VIFN.SW) as of Nov 4, 2026 is 494.80 M CHF. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 266.60 M CHF — a change of 85.60% (higher).

EBITDA

494.80 MCHF

YoY

85.60%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Vifor Pharma is 2021 494.80 M CHF. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Vifor Pharma was 2020 266.60 M CHF. It decreases by 85.60% higher compared to the previous year.

The Vifor Pharma EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2014
360.92 M CHF
Jan 1, 2015
531.13 M CHF
Jan 1, 2016
356.24 M CHF
Jan 1, 2017
134.30 M CHF
Jan 1, 2018
184.20 M CHF
Jan 1, 2019
325.00 M CHF
Jan 1, 2020
266.60 M CHF
Jan 1, 2021
494.80 M CHF
The Vifor Pharma EBITDA history
YEAREBITDAYoY
494.80 MCHF+85.60%
266.60 MCHF-17.97%
325.00 MCHF+76.44%
184.20 MCHF+37.16%
134.30 MCHF-62.30%
356.24 MCHF-32.93%
531.13 MCHF+47.16%
360.92 MCHF—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vifor Pharma Stock analysis

What does Vifor Pharma do? Vifor Pharma AG is a leading pharmaceutical company based in St. Gallen, Switzerland. The company has a long history and over 100 years of experience in the manufacturing of pharmaceutical products. It was founded in 1872 as Etablissements Gallois and has undergone various mergers and acquisitions. Today, it is part of the global Galenica Group and has branches in over 30 countries. Vifor Pharma AG focuses on the development and production of medications for the treatment of iron deficiency and kidney diseases. It diversifies its business across different market segments and geographic regions. The company's well-known products include iron preparations sold under different brands such as Ferinject, Injectafer, and Venofer, used for the treatment of iron deficiency anemia in both intravenous and tablet forms. another important business area for Vifor Pharma AG is nephrology, with a wide range of kidney and dialysis products available, including treatments for hyperphosphatemia and anemia in dialysis patients. To strengthen its innovation, the company has invested in partnerships, such as an exclusive license for the distribution of Vadadustat, an oral medication for the treatment of anemia in chronic kidney disease. Vifor Pharma AG has also invested in the digitalization and data-driven technologies, acquiring a stake in the Austrian company medisign GmbH in 2020 to expand its expertise in digital health and telemedicine. In terms of sustainability, the company aims to be carbon-neutral by 2025 and has implemented measures to reduce its CO2 footprint. With its long history, diverse portfolio of products and services, and investments in innovation and sustainability, Vifor Pharma AG is well-positioned for future success. Vifor Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vifor Pharma stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Vifor Pharma is 494.80 M CHF in 2021.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Vifor Pharma changed from 266.60 M CHF to 494.80 M CHF, representing a 85.60% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Vifor Pharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CHF is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Vifor Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Vifor Pharma

All Key Metrics — Vifor Pharma